Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β
Abstract
Exposure of rat hippocampal neurons to the peptide amyloid beta (A beta) (25-35) as well as A beta (1-40) peptides enhances phosphorylation of tau to a paired helical filament (PHF)-state through activation of tau protein kinase I (TPK I)/glycogen synthase kinase-3 beta (GSK-3 beta) [Busciglio, J., Lorenzo, A., Yeh, J. and Yankner, B.A., Neuron, 14 (1995) 879-888; Takashima, A., Ishiguro, K., Noguchi, K., Michel, G., Hoshi, M., Sato, K., Takahashi, M., Hoshino, T., Uchida, T. and Imahori, K., Neurosci. Meeting Abstr., 671 (1995) 17]. In order to examine the effects of A beta treatment on intracellular signaling mechanism, we have investigated the role of phosphatidyl inositol-3 (PI-3) kinase in the phosphorylation of tau. A beta (25-35) exposure induced an inactivation of PI-3 kinase and an activation of TPK I/GSK-3 beta in rat hippocampal culture. Wortmannin, an inhibitor of PI-3 kinase, also activated TPK I/GSK-3 beta, leading to an enhancement of tau phosphorylation and neuronal death in hippocampal culture. These results suggest that A beta (25-35) inhibition of PI-3 kinase results in the activation of TPK I/GSK-3 beta, the phosphorylation of tau, and resultant neuronal death in rat hippocampal neurons.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GSK3β can orchestrate pathological tau phosphorylation at over two-dozen disease-associated sites.
“The GSK3β can orchestrate pathological tau-phosphorylation at over two-dozen disease-associated sites [181–184].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [183]
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · see citing works
Mattson, M. P., Cheng, B., Davis, D. G., Bryant, K., Lieberburg, I. M., & Rydel, R. E. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,627 · see citing works
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417 · see citing works
Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor
Yao, R., & Cooper, G. M. (1995) · Science · doi:10.1126/science.7701324 · Cited by 1,390 · see citing works
Arcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,146 · see citing works
Pike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699 · see citing works
β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595 · see citing works
Welsh, G. I., & Proud, C. G. (1993) · Biochemical Journal · doi:10.1042/bj2940625 · Cited by 397 · see citing works
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
Takashima, A., Noguchi, K., Sato, K., Hoshino, T., & Imahori, K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7789 · Cited by 381 · see citing works
Self-citationKimura, K. D., Hattori, S., Kabuyama, Y., Shizawa, Y., Takayanagi, J., Nakamura, S., Toki, S., Matsuda, Y., Onodera, K., & Fukui, Y. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32260-3 · Cited by 333 · see citing works
Eldar-Finkelman, H., Seger, R., Vandenheede, J. R., & Krebs, E. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.987 · Cited by 214 · see citing works
Welsh, G. I., Foulstone, E. J., Young, S. W., Tavaré, J. M., & Proud, C. G. (1994) · Biochemical Journal · doi:10.1042/bj3030015 · Cited by 200 · see citing works
The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells
Saito, Y., Vandenheede, J. R., & Cohen, P. (1994) · Biochemical Journal · doi:10.1042/bj3030027 · Cited by 146 · see citing works
β-Amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology
Pike, C. J., Cummings, B. J., & Cotman, C. W. (1992) · Neuroreport · doi:10.1097/00001756-199209000-00012 · Cited by 131 · see citing works
β-Amyloid precursor protein and alzheimer's disease: The peptide plot thickens
Mattson, M. P., & Rydel, R. E. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90068-9 · Cited by 59 · see citing works
Latimer, D. A., Gallo, J.-M., Lovestone, S., Miller, C. C. J., Hugh Reynolds, C., Marquardt, B., Stabel, S., Woodgett, J. R., & Anderton, B. H. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00434-b · Cited by 48 · see citing works
A Specific Immunoprecipitation Assay for the Protein Kinase FA/Glycogen Synthase Kinase 3
Lint, J. V., Khandelwal, R. L., Merlevede, W. J., & Vandenheede, J. R. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1018 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216 · see citing works
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,429 · see citing works
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · see citing works
Lucas, J. J., Hernández, F., Gómez‐Ramos, P., Morán, M. A., Hen, R., & Avila, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 903 · see citing works
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774 · see citing works
Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model
Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K. H., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.013 · Cited by 707 · see citing works
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631 · see citing works
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624 · see citing works
Bhat, R. V., Xue, Y., von Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 557 · see citing works
Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536 · see citing works
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · see citing works
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451 · see citing works
Leon, R. M., Garcı́a, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 442 · see citing works
Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau
Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M. H., Yamaguchi, H., Sugihara, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9637 · Cited by 404 · see citing works
Self-citationGlycogen synthase kinase 3: a drug target for CNS therapies
Bhat, R. V., Haeberlein, S. L. B., & Ávila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408 · see citing works
GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s335 · Cited by 395 · see citing works
Self-citationα-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works
GSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359 · see citing works
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371 · see citing works
MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease
Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 326 · see citing works
Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329 · see citing works
Wnt signaling in the nervous system and in Alzheimer's disease
Inestrosa, N. C., & Varela-Nallar, L. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt051 · Cited by 324 · see citing works
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372 · see citing works
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314 · see citing works
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300 · see citing works
Wnt signaling function in Alzheimer’s disease
Ferrari, G. V. D., & Inestrosa, N. C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00021-7 · Cited by 288 · see citing works
Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287 · see citing works
Self-citationEngel, T., Hernández, F., Ávila, J., & Lucas, J. J. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 261 · see citing works
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid
Kanninen, K. M., Malm, T., Jyrkkänen, H.-K., Goldsteins, G., Keksa-Goldsteine, V., Tanila, H., Yamamoto, M. P., Ylä‐Herttuala, S., Levonen, A., & Koıstınaho, J. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.010 · Cited by 256 · see citing works
Developmental expression and localization of glycogen synthase kinase-3β in rat brain
Leroy, K., & Brion, J. (1999) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(99)00012-5 · Cited by 241 · see citing works
Rojo, A. I., de Sagarra, M. R., & Cuadrado, A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05124.x · Cited by 241 · see citing works
Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases
Pajares, M., Cuadrado, A., & Rojo, A. I. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.006 · Cited by 219 · see citing works
Zhang, L., Yu, H.-M., Zhao, X., Lin, X.-F., Tan, C., Cao, G.-X., & Wang, Z.-W. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.021 · Cited by 215 · see citing works
Olivieri, G., Brack, C., Müller-Spahn, F., Stähelin, H. B., i, M. H., Renard, P., Brockhaus, M., & Hock, C. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740231.x · Cited by 210 · see citing works
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited
Harwood, A. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001618 · Cited by 208 · see citing works
β-Amyloid impairs axonal BDNF retrograde trafficking
Poon, W. W., Blurton-Jones, M. M., Tu, C. H., Feinberg, L. M., Chabrier, M. A., Harris, J. W., Jeon, N. L., & Cotman, C. W. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.012 · Cited by 198 · see citing works
The GSK3β signaling cascade and neurodegenerative disease
Kaytor, M. D. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00320-3 · Cited by 196 · see citing works
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · see citing works
Boutajangout, A., Leroy, K., Authelet, M., Anderton, B. H., Brion, J., & Woodgett, J. R. (2002) · Acta Neuropathologica · doi:10.1007/s004010100435 · Cited by 186 · see citing works
Akt: Versatile Mediator of Cell Survival and Beyond
Kim, D., & Chung, J. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.106 · Cited by 182 · see citing works
GSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177 · see citing works
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., & Beurel, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.010 · Cited by 172 · see citing works
Tapia‐Rojas, C., Aránguiz, F. C., Varela‐Nallar, L., & Inestrosa, N. C. (2015) · Brain Pathology · doi:10.1111/bpa.12255 · Cited by 168 · see citing works
Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance
Balaraman, Y., Limaye, A. R., Levey, A. I., & Srinivasan, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5597-y · Cited by 167 · see citing works
Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β
Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167 · see citing works
Lee, G. S., & Leugers, C. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00004-7 · Cited by 166 · see citing works
GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration
Salcedo‐Tello, P., Ortiz‐Matamoros, A., & Arias, C. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/189728 · Cited by 163 · see citing works
Wnts in adult brain: from synaptic plasticity to cognitive deficiencies
Oliva, C. A., Vargas, J. Y., & Inestrosa, N. C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00224 · Cited by 162 · see citing works
Maggirwar, S. B., Tong, N., Ramirez, S. H., Gelbard, H. A., & Dewhurst, S. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730578.x · Cited by 164 · see citing works
Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 163 · see citing works
Deconstructing GSK‐3: The Fine Regulation of Its Activity
Medina, M., & Wandosell, F. G. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/479249 · Cited by 163 · see citing works
GSK-3β at the Intersection of Neuronal Plasticity and Neurodegeneration
Jaworski, T., Banach, E., & Gralec, K. (2019) · Neural Plasticity · doi:10.1155/2019/4209475 · Cited by 161 · see citing works
GSK3β and tau protein in Alzheimer's disease and epilepsy
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158 · see citing works
Parr, C., Carzaniga, R., Gentleman, S., LEUVEN, F. V., Walter, J., & Sastre, M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00930-12 · Cited by 155 · see citing works
Malm, T., Iivonen, H., Goldsteins, G., Keksa-Goldsteine, V., Ahtoniemi, T., Kanninen, K. M., Salminen, A., Auriola, S. O. K., van Groen, T., Tanila, H., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0059-07.2007 · Cited by 154 · see citing works
Flavonoid‐mediated presenilin‐1 phosphorylation reduces Alzheimer's disease β‐amyloid production
Rezai-Zadeh, K. P., Shytle, R. D., Bai, Y., Tian, J., Hou, H., Mori, T., Zeng, J., Obregon, D. F., Town, T., & Tan, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00344.x · Cited by 153 · see citing works
GSK‐3: A key player in neurodegeneration and memory
Giese, K.-P. (2009) · IUBMB Life · doi:10.1002/iub.187 · Cited by 150 · see citing works
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142 · see citing works
ER stress is involved in Aβ‐induced GSK‐3β activation and tau phosphorylation
Resende, R., Ferreiro, E. B., Pereira, C., & Oliveira, C. R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21648 · Cited by 142 · see citing works
Lithium and Therapeutic Targeting of GSK-3
Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 145 · see citing works
GSK-3β Is Required for Memory Reconsolidation in Adult Brain
Kimura, T., Yamashita, S., Nakao, S., Park, J.-M., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003540 · Cited by 136 · see citing works
Self-citationNormal and Pathological Tau Proteins as Factors for Microtubule Assembly
Delacourte, A., & Buée, L. (1997) · International review of cytology · doi:10.1016/s0074-7696(08)62588-7 · Cited by 136 · see citing works
New Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works
Self-citationMiller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., & Liao, D. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12507 · Cited by 131 · see citing works
Search for a common mechanism of mood stabilizers
Harwood, A. J., & Agam, G. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00187-4 · Cited by 132 · see citing works
Therapeutic strategies for tau mediated neurodegeneration
Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 129 · see citing works
The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease
Belkouch, M., Hachem, M., Elgot, A., Van, A. L., Picq, M., Guichardant, M., Lagarde, M., & Bernoud‐Hubac, N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.002 · Cited by 128 · see citing works
Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease
Fuentealba, R. A., Farı́as, G. G., Scheu, J., Bronfman, M., Marzolo, M., & Inestrosa, N. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.018 · Cited by 126 · see citing works
Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3
Koh, S., Noh, M., & Kim, S. H. (2007) · Brain Research · doi:10.1016/j.brainres.2007.10.064 · Cited by 126 · see citing works
Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease
Folke, J., Pakkenberg, B., & Brudek, T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1103-z · Cited by 123 · see citing works
Epigenetically regulated microRNAs in Alzheimer's disease
van den Hove, D., Kompotis, K., Lardenoije, R., Kenis, G., Mill, J. S., Steinbusch, H. W. M., Lesch, K., Fitzsimons, C. P., Strooper, B. D., & Rutten, B. P. F. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.082 · Cited by 119 · see citing works
Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome
Ebrahim, A. S., Shimohata, A., Akagi, T., Yu, W., Yamaguchi, M., Murayama, M., Chui, D., Takeuchi, T., Amano, K., Subramhanya, K. H., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl211 · Cited by 117 · see citing works
Self-citationTokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348300 · Cited by 117 · see citing works
Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Ávila, J., Bogónez, E., & Díaz‐Nido, J. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01150.x · Cited by 116 · see citing works
Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures
Egaña, J. T., Zambrano, C. A., Núñez, M. T., González-Billault, C. E., & Maccioni, R. B. (2003) · BioMetals · doi:10.1023/a:1020727218493 · Cited by 114 · see citing works
Tissue plasminogen activator mediates amyloid‐induced neurotoxicity via Erk1/2 activation
Medina, M. G., Ledesma, M. D., Domínguez, J. E., Medina, M., Zafra, D., Alameda, F., Dotti, C. G., & Navarro, P. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600650 · Cited by 114 · see citing works
Engel, T., Lucas, J. J., Gómez‐Ramos, P., Morán, M. A., Ávila, J., & Hernández, F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.010 · Cited by 111 · see citing works
Jin, N., Yin, X., Yu, D., Cao, M., Gong, C., Iqbal, K., Ding, F., Gu, X., & Liu, F. (2015) · Scientific Reports · doi:10.1038/srep08187 · Cited by 107 · see citing works
Zeng, K., Ko, H., Yang, H. O., & Wang, X. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.020 · Cited by 106 · see citing works
Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration
Rao, S. S., & Adlard, P. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00276 · Cited by 105 · see citing works
Griffith, L. S., & Schmitz, B. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00439.x · Cited by 104 · see citing works
Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein
Frasier, M. A., Walzer, M., McCarthy, L., Magnuson, D. J., Lee, J. M., Haas, C. A., Kahle, P. J., & Wolozin, B. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.016 · Cited by 103 · see citing works
Fan, S.-J., Huang, F.-I., Liou, J., & Yang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0688-5 · Cited by 102 · see citing works
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
Jembrek, M. J., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 99 · see citing works
Eidenmüller, J., Fath, T., Hellwig, A., Reed, J., Sontag, E., & Brandt, R. (2000) · Biochemistry · doi:10.1021/bi001290z · Cited by 117 · see citing works
Olivieri, G., Baysang, G., Meier, F., Müller-Spahn, F., Stähelin, H. B., Brockhaus, M., & Brack, C. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00090.x · Cited by 98 · see citing works
Griebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97 · see citing works
Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β
Cedazo-Mı́nguez, Á., Popescu, B. O., Blanco‐Millán, J. M., Akterin, S., Pei, J. ‐., Winblad, B. G., & Cowburn, R. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02088.x · Cited by 97 · see citing works
Lee, S. J., Chung, Y. H., Joo, K. M., Lim, H. C., Jeon, G. S., Kim, D., Lee, W. B., Kim, Y. S., & Ik, C. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.026 · Cited by 96 · see citing works
Kelly, S., Zhao, H., Sun, G. H., Cheng, D., Qiao, Y., Luo, J., Martin, K., Steinberg, G. K., Harrison, S. D., & Yenari, M. A. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.004 · Cited by 95 · see citing works
Schäfer, M., Goodenough, S., Moosmann, B., & Behl, C. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.037 · Cited by 93 · see citing works
Wnt signaling: Role in LTP, neural networks and memory
Oliva, C. A., Vargas, J., & Inestrosa, N. C. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.006 · Cited by 90 · see citing works
Recent developments of protein kinase inhibitors as potential AD therapeutics
Tell, V., & Hilgeroth, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00189 · Cited by 90 · see citing works
Three-Dimensional Structures of the Amyloid β Peptide (25−35) in Membrane-Mimicking Environment
Kohno, T., Kobayashi, K., Maeda, T., Sato, K., & Takashima, A. (1996) · Biochemistry · doi:10.1021/bi961598j · Cited by 90 · see citing works
Self-citationRyder, J. W., Yuan, S., & Ni, B. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.07.004 · Cited by 89 · see citing works
Frizzled‐1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers
Chacón, M. A., Varela‐Nallar, L., & Inestrosa, N. C. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21497 · Cited by 87 · see citing works
Oxidative stress promotes τ dephosphorylation in neuronal cells: the roles of cdk5 and PP1
Zambrano, C. A., Egaña, J. T., Núñez, M. T., Maccioni, R. B., & González-Billault, C. E. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.03.007 · Cited by 85 · see citing works
Role of GSK‐3β in Alzheimer's disease pathology
Planel, E., Sun, X., & Takashima, A. (2002) · Drug Development Research · doi:10.1002/ddr.10100 · Cited by 85 · see citing works
Self-citationRegulation of Cell Survival Mechanisms in Alzheimer′s Disease by Glycogen Synthase Kinase‐3
Mines, M. A., Beurel, E., & Jope, R. S. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/861072 · Cited by 85 · see citing works
GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease
Bhat, R. V., & Budd, S. L. (2002) · Neurosignals · doi:10.1159/000067423 · Cited by 85 · see citing works
- Authors
- Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., & Imahori, K.
- Corresponding author
- Takashima, Akihiko
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 1996-01
- Volume
- 203
- Issue
- 1
- Pages
- 33-36
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W1986537744
- Cited by
- 260
- References
- 18
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 5 · 2023: 9 · 2022: 4 · 2021: 9 · 2020: 5 · 2019: 11 · 2018: 12 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 15 · 2013: 13 · 2012: 13
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid beta 25-35, Aβ40, phosphatidylinositol 3-kinase, glycogen synthase kinase-3β, tau phosphorylation, paired helical filaments, hippocampal neurons, neuronal cell death, wortmannin, Alzheimer's disease
- MeSH terms
- Wortmannin, Alzheimer Disease, Androstadienes, Animals, Cells, Cultured, Dose-Response Relationship, Drug, Enzyme Inhibitors, Glycogen Synthase, Hippocampus, Phosphotransferases, Amyloid beta-Protein Precursor, tau Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review